Abstract Details

Title 6-month Real-world Effectiveness of Fremanezumab in Patients with Migraine who Switched from Another mAb Targeting the CGRP Pathway (Subgroup Analysis from FINESSE)

Topic Headache

Presentation(s) P4 - Poster Session 4 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-006

Objective To evaluate effectiveness and tolerability of fremanezumab administered in migraine patients, who switched from a previous anti-calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), as part of their routine disease management.

Background Fremanezumab is a humanized mAb that selectively targets the CGRP ligand and is authorized for preventive treatment of episodic (EM) and chronic migraine (CM) in adults.

Design/Methods FINESSE is an ongoing prospective, non-interventional study in adults with EM or CM. The observation period is 24 months. The primary endpoint is the proportion of patients reaching ≥50% reduction in average number of monthly migraine days (MMD) during the 6-month period after the first dose of fremanezumab. Further measures include monthly average number of migraine days, MIDAS (Migraine Disability Assessment), HIT-6 (6-Item Headache Impact Test), and acute medication use. In this subgroup analysis, 6-month-data in patients who experienced poor effectiveness or tolerability with a prior anti-CGRP pathway mAb and therefore switched to fremanezumab are presented.

Results Of 140 patients (47.6 ± 11.5 years, 84.7% female), 54 (38.6%) achieved a MMD reduction of ≥ 50% over 6 months (EM: 44.3%, CM: 31.2%). Number of MMD decreased from 13.3 ± 6.42 at baseline, by 6.1 ± 5.47 (month 6). Acute migraine medication was used on 9.5 ± 4.92 days/month at baseline and decreased to 5.0 ± 3.86 days/month (month 6). MIDAS score decreased from 71.1 ± 57.1 (baseline, N=68), to 43.7 ± 44.4 (month 6, N=48). HIT-6 score decreased from 65.8 ± 4.8 (baseline, N=78), to 59.6 ± 7.9 (month 6, N=55).

Conclusions In this interim analysis of the FINESSE non-interventional study, 38.6% of anti-CGRP pathway mAb-non-responders benefit (≥50% response) from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing inadequate efficacy or poor tolerability with prior other anti-CGRP pathway mAb use.

Authors/Disclosures
Verena Ramirez Campos, MD (Teva) PRESENTER	Dr. Ramirez Campos has received personal compensation for serving as an employee of teva.
Andreas Straube	Andreas Straube has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Andreas Straube has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Andreas Straube has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis.
Gregor Broessner	Gregor Broessner has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Gregor Broessner has received personal compensation in the range of $0-$499 for serving as a Consultant for TEVA. Gregor Broessner has received personal compensation in the range of $0-$499 for serving as a Consultant for Lilly. Gregor Broessner has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Gregor Broessner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Gregor Broessner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly.
Charly Gaul (Headache Center Frankfurt, Frankfurt am Main, Germany)	The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of an immediate family member of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vectura. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Charly Gaul has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merz. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dr. Reddy. Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Perfood. Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reckitt-Benckiser . The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Hormosan. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chordate. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Dr. Reddy. The institution of Charly Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie.
Xenia Hamann (Teva GmbH)	Xenia Hamann has received personal compensation for serving as an employee of Teva GmbH.
Joachim Hipp (Teva)	No disclosure on file
Torsten Kraya, MD (Klinikum St. Georg Leipzig, Klinik für Neurologie)	Dr. Kraya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA, Novartis, Lilly. Dr. Kraya has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA, Novartis, Lilly, Hormosan, Abbvie.
Lars Oliver Neeb (Helios Global Health GmbH)	No disclosure on file

��ɫ��

��ɫ��